2 Bello Y M, Falabella A F, Eaglstein W H. Tissue-engineered skin. Current status in wound healing. Am J Clin Dermatol, 2001, 2: 305-313
[3]
3 Rheinwald J G, Green H. Serial cultivation of strains of human epidermal keratinocytes: the formation of keratinizing colonies from single cells. Cell, 1975, 6: 331-343
[4]
4 O''Connor N E, Mulliken J B, Banks-Schlegel S, et al. Grafting of burns with cultured epithelium prepared from autologous epidermal cells. Lancet, 1981, 1: 75-78
[5]
5 Burke J F, Yannas I V, Quinby W C Jr, et al. Successful use of a physiologically acceptable artificial skin in the treatment of extensive burn injury. Ann Surg, 1981, 194: 413-428
[6]
6 Wainwright D J. Use of an acellular allograft dermal matrix (AlloDerm ) in the management of full-thickness burns. Burns. 1995, 21: 243-248
[7]
7 Wainwright D, Madden M, Luterman A, et al．Clinical evaluation of an acellular allograft dermal matrix in full-thickness burns. J Burn Care Rehabil, 1996, 17: 124-136
9 Cichowski A, Kawecki M, Glik J, et al. Literature review concerning cell and skin substitute cultures obtained by means of tissue engineering used in the treatment of burns. Pol Przegl Chir, 2014, 86: 202-210
[10]
10 Eaglstein W H, Falanga V. Tissue Engineering and the development of apligraf a human skin equivalent. Adv Wound Care, 1998, 11: 1-8
[11]
16 Jimenez P A, Jimenez S E. Tissue and cellular approaches to wound repair. Am J Surg, 2004, 187: 56S-64S
[12]
17 Griffiths M, Ojeh N, Livingstone R, et al. Survival of Apligraf in acute human wounds. Tissue Eng, 2004, 10: 1180-1195
21 Ramos-e-SilvaM, Ribeiro de Castro M C. New dressings, including tissue-engineered living skin Clin. Dermatol, 2002, 20: 715-723
[17]
22 Price R D, Berry M G, Navsaria H A. Hyaluronicacid: the scientific and clinical evidence. J Plast Reconstr Aesthet Surg, 2007, 60: 1110-1119
[18]
26 Naughton G, Mansbridge J, Gentzkow G. A metabolically active human dermal replacement for the treatment of diabetic foot ulcers. Artificial Organs, 1997, 21: 1203-1210
[19]
27 Australian Safety and Efficacy Register of New Interventional Procedures-Surgical. Use of Transcyte. New and Emerging Techniques-Surgical, 2001 Oct
[20]
28 Travia G, Palmisano P A, Cervelli V, et al. The use of fibroblast and keratinocyte cultures in burns treatment. Ann of Burns and Fire Disast, 2003, 16: XVI
[21]
29 Purdue G F, Hunt J L, Still J M Jr, et al. A multicenter clinical trial of a biosynthetic skin replacement, Dermagraft-TC, compared with cryopreserved human cadaver skin for temporary coverage of excised burn wounds. J Burn Care Rehabil, 1997, 18: 52-57
[22]
30 Pangarkar N, Pharoah M, Nigam A, et al. Advanced Tissue Sciences Inc.: learning from the past, a case study for regenerative medicine. Regen Med, 2010, 5: 823-835
[23]
31 Munster A M. Cultured skin for massive burns: a prospective, controlled trial. Ann Surg, 1996, 224: 372-375
[24]
32 The file of US Food and Drug Administration approved Epicel as Humanitarian Device Exemption, Accessed OCT 25 2007
[25]
33 Tausche A K, Skaria M, B？hlen L, et al. An autologous epidermal equivalenttissue-engineered from follicular outer root sheathkeratinocytes is as effective as split-thickness skin autograftin recalcitrant vascular leg ulcers. Wound Repair Regen, 2003, 11: 248-252
[26]
34 Ortega-Zilic N, Hunziker T, L？uchli S, et al. EpiDex？ Swiss field trial 2004-2008. Dermatolog, 2010, 221: 365-72
[27]
35 Zweifel C J, Contaldo C, K？hler C, et al. Initial experiences using non-cultured autologous keratinocyte suspension for burn wound closure. J Plast Reconstr Aesthet Surg, 2008, 61: e1-e4
[28]
36 The file of CELLSPRAY？ APPROVED IN GREECE. 2006 Nov 8
[29]
37 Shakespeare P G. The role of skin substitutes in the treatment of burn injuries. Clin Dermatol, 2005, 23: 413-418
[30]
38 Gryskiewicz J M, Rohrich R J, Reagan B J, et al. The use of alloderm for the correction of nasal contour deformities. Plast Reconstr Surg,2001, 107: 561-570
[31]
39 Valentin J E, Badylak J S, McCabe G P, et al. Extracellular matrix bioscaffolds for orthopaedic applications. A comparative histologic study. J Bone Joint Surg Am,2006, 88: 2673-2686
[32]
40 Furukawa K, Pichora J, Steinmann S, et al. Efficacy of interferencescrew and double-docking methods using palmaris longus and GraftJacket for medial collateral ligament reconstruction of the elbow. J Shoulder Elbow Surg, 2007, 16: 449-453
[33]
41 Aurora A, McCarron J, Iannotti J P, et al. Commercially available extracellular matrix materials for rotator cuff repairs: state of the art and future trends. J Shoulder Elbow Surg, 2007, 16: S171-S178
[34]
42 Clinical Coverage Guidelines-Skin Substitutes for Wound Healing. Boston Medical CenterHealthNet Plan. Policy Number: OCA: 3.710. Effective Date: 06/01/11, page1-11
[35]
43 Copyright？2012 KCl Licensing, Inc. All Rights Reserved. GraftJacket@ regenerative tissue matrix instruciton for use, Part NO. 173P0020 Rev. B, 2012 Feb
[36]
44 Shevchenko R V, James S L, James S E. A review of tissue-engineered skin bioconstructs available for skin reconstruction. J R Soc Interface, 2010, 7: 229-258
[37]
45 Mostow E N, Haraway G D, Dalsing M, et al. Effectiveness of an extracellular matrix graft (OASIS Wound Matrix) in the treatment of chronic leg ulcers: a randomized clinical trial. J Vasc Surg, 2005, 41: 837-843
[38]
46 The file of US Food and Drug Administration for OASIS. Medical Devices. Special 510(K) Summary, 510(k) Number: K061711, Accessed JUL 19 2006
[39]
47 Stern R, McPherson M, Longaker M T, et al. Histologic study of artificial skin used in the treatment of full-thickness thermal injury. J Burn Care Rehabil, 1990, 11: 7-13
[40]
48 Dantzer E, Braye F M. Reconstructive surgery using an artificial dermis (Integra): results with 39 grafts. Br J Plast Surg, 2001, 54: 659-664
[41]
49 Klein R L, Rothmann B F, Marshall R. Biobrane—a useful adjunct in the therapy of outpatient burns. J Pediatr Surg, 1984, 19: 846-847
[42]
50 The file of US Food and Drug Administration for Biobrane. Medical Devices. 510(K) Summary, 510(k) Number: K082869, Accessed FEB 6 2009
[43]
51 Eungdamrong N J, Higgins C, Guo Z, et al. Challenges and promises in modeling dermatologic disorders with bioengineered skin. Exp Biol Med, 2014, 239: 1215-1224
[44]
52 Leroy M, Lafleur M, Auger M, et al. Characterization of the structure of human skin substitutes by infrared microspectroscopy. Anal Bioanal Chem, 2013, 405: 8709-8718
[45]
53 Leroy M, Labbé J F, Ouellet M, et al. A comparative study between human skin substitutes and normal human skin using Raman microspectroscopy. ActaBiomaterialia, 2014, 10: 2703-2711
[46]
54 Sander E A, Lynch K A, Boyce S T. Development of the mechanical properties of engineered skin substitutes after grafting to full-thickness wounds. J Biomech Eng, 2014, 136: 051008
[47]
55 Dewey C F Jr, Bussolari S R, Gimbrone M A Jr, et al. The dynamic response of vascular endothelial cells to fluid shear stress. J Biomech Eng, 1981, 103: 177-185
[48]
56 Sriwiriyanont P, Lynch K A, McFarland K L, et al. Characterization of hair follicle development in engineered skin substitutes. PLoS One, 2013, 8: e65664
[49]
64 Catalano E, Cochis A, Varoni E, et al. Tissue-engineered skin substitutes: an overview. J Artif Organs, 2013, 16: 39
66 Asakawa N, Shimizu T, Tsuda Y, et al. Pre-vascularization of in vitro three-dimensional tissues created by cell sheet engineering. Biomaterials, 2010, 31: 3903-3909
[52]
67 Haraguchi Y, Sekine W, Shimizu T, et al. Development of a new assay system for evaluating the permeability of various substances through three-dimensional tissue. Tissue Eng Part C Methods, 2010, 16: 685-692
[53]
11 Bell E, Ehrilich H P, Buttle D J, et al. Livingtissue formed in vitro and accepted asskin-equivalent tissue of full thickness. Science, 1981, 211: 1052-1054
[54]
12 Parenteau N L, Bilbo P, Nolte C J M, et al. The organotypic culture of human skinkeratinocytes and fibroblasts to achieveform and function. Cytotechnology, 1992, 9: 163-171
[55]
13 Wilkins L M, Watson S R, Prosky S J, et al. Development of a bilayered living skin construct for clinical applications. Biotechnol Bioeng, 1994, 43: 747-756
[56]
14 Bilbo P R, Nolte C J M, Oleson M A, et al. Skin in complex culture: the transition from “culture” phenotype to organotypicphenotype. Cutaneous Ocul Toxicol, 1993, 12: 183-196
[57]
15 Snyder D L, Sullivan N, Schoelles K M. Skin Substitutes for Treating Chronic Wounds. Technology Assessment Report, Project ID: HCPR0610, 2012-12-18
[58]
23 Johnsen S, Ermuth T, Tanczos E, et al. Treatment of therapy-refractive ulceracruris of various origins with autologous keratinocytes infibrin sealant. Vasa, 2005, 34: 25-29
[59]
24 Vanscheidt W, Ukat A, Horak V, et al. Treatment of recalcitrant venousleg ulcers with autologous keratinocytes in fibrin sealant: a multinational randomized controlled clinical trial. Wound Repair Regen, 2007, 15: 308-315
[60]
25 Marston W A, Hanft J, Norwood P, et al. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial. Diabetes Care, 2003, 26: 1701-1705
[61]
57 Jeremias Tda S, Machado R G, Visoni S B, et al. Dermal substitutes support the growth of human skin-derived mesenchymal stromal cells: potential tool for skin regeneration. PLoS One,2014, 9: e89542
[62]
58 Jin G, Prabhakaran M P, Ramakrishna S. Stem cell differentiation to epidermal lineages on electrospunnanofibrous substrates for skin tissue engineering. Acta Biomater, 2011, 7: 3113-3122
[63]
59 Hansen S L, Voigt D W, Wiebelhaus P, et al. Using skin replacement products to treat burns and wounds. Adv Skin Wound Care, 2001, 14: 37-44
[64]
60 国家食品药品监督管理局. 关于发布组织工程医疗产品研究及申报相关要求的通告. 国食药监械
[65]
762号, 2007-12-18
[66]
61 Bioengineered Tissue Products for Wound Treatment and Surgical Intervention. MEDICAL POLICY. POLICY NUMBER: 7.01.35, CATEGORY: Technology Assessment. Effective date: 01/17/02. Page: 1-15
[67]
62 Pfuhler S, Fautz R, Ouedraogo G, et al. The cosmetics europe strategy for animal-free genotoxicity testing: project status up-date. Toxicol In Vitro, 2014, 28: 18-23
[68]
63 Casas J W, Lewerenz G M, Rankin E A, et al. In vitro human skin irritation test for evaluation of medical device extracts. Toxicol In Vitro, 2013, 27: 2175-2183
